Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung

HIDETAKA URAMOTO, SOHSUKE YAMADA and TAKESHI HANAGIRI
Anticancer Research November 2010, 30 (11) 4717-4720;
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka@med.uoeh-u.ac.jp
SOHSUKE YAMADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI HANAGIRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: DeltaNp63 is an isoform of the p53 homolog p63, which lacks an amino-terminal transactivation domain. The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker. Patients and Methods: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma. Results: Of 17 cases, 13 (76.5%) and 14 (82.4%) cases showed positive staining for deltaNp63 and HMWCK in the tumor cells, respectively. It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors. Interestingly, positive expression of deltaNp63 was detected in one case with a negative expression of HMWCK. Conclusion: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.

  • DeltaNp63
  • immunohistochemistry
  • squamous cell carcinoma
  • non-small cell lung cancer

The essential histological diagnosis for lung cancer has been its classification into small cell carcinoma (SCLC) or non-small cell carcinoma (NSCLC) because treatment did not differ between the variants. However, several drugs have become available with indications dependent on the precise definition of tumor subtype, in relation to both the efficacy and safety for specific histology. For example, the epidermal growth factor receptor – tyrosine kinase inhibitor (EGFR–TKI) such as gefitinib have superior efficacy in patients harboring a somatic mutation, which is usually observed in only adenocarcinoma (AD) (1). Squamous carcinoma (SQ) histology is now a contraindication for bevacizumab due to fatal adverse events (2). Pemetrexed is also contraindicated in SQ with no significant efficacy, but has superior efficacy in non-SQ over standard platinum-doublet chemotherapy (3). Therefore, the dichotomization of the NSCLC subtype into SQ and AD is increasingly required for both diagnostic meaning and therapeutic selection. Furthermore, the therapeutic strategy for adenosquamous carcinoma (ADSQ) remains unclear. ADSQs are the most suitable research object to determine a useful marker because these tumors include both SQ and AD components (4).

The tumor suppressor p53 and its two homolog p63 and p73, form a family of proteins (5). P63 and p73 show a much greater molecular complexity than p53 because they are both expressed as multiple alternatively spliced C-terminal isoforms, and as an N-terminally deleted form (6). In addition, several other factors, such as post-translational modifications, result in the subtle modulation of their biological effects (7). P63 knockout animals showed defects in epidermal development, suggesting a role of p63 in regulating differentiation in epithelial cells (8). P63 gene amplification and protein overexpression are more often detected in a variety of carcinomas of the head and neck (9), lung (10), and skin (11). Therefore, p63 may play an important role in tumor progression. On the other hands, the overexpression of DeltaNp63, which is a different isoform due to alternative splicing (12), often enhances the oncogenic growth of squamous cell carcinomas (9). Traditionally, p63 has been used as an immunomarker for SQ on tissue sections (13). However, an immunohistochemical (IHC) examination of the expression of p63 used a nonspecific antibody, which reacts not only with the transactivating domain (TA)-p63, but also with deltaNp63 (14, 15). Furthermore, the positive expression of deltaNp63 on SQ was significantly higher than on AD (5).

This study attempted to identify a specific marker to detect only the SQ component of ADSQs using a commercially available antibody. This study investigated the ability of deltaNp63 to discriminate the histology in NSCLC and compared it to high molecular weight cytokeratin (HMWCK), which is known to be a differential marker for SQ and AD (16).

Patients and Methods

Patient samples. The characteristics and clinicopathological factors were evaluated retrospectively. One thousand and one hundred thirty-four patients with primary lung cancer underwent a surgical resection between June 1995 to March 2010 at the Second Department of Surgery at University of Occupational and Environmental Health, Kitakyushu, Japan. The established criteria classified an ADSQ as a tumor containing at least 20% of AD and SQ each (4). Specimens from each of these patients were reviewed critically by one (S.Y.) pathologist. This study evaluated 17 cases (1.5%) with ADSQ. The characteristics of the patients with ADSQ are shown in Table I. Patients included 6 males and 11 females with a mean age of 68.5 years, ranging in age from 48 to 86 years. Institutional Review Board-approved informed consent was obtained from all patients for the use of tumor tissue specimens collected at the time of tumor resection.

Immunohistochemical (IHC) staining in paraffin-embedded tumor samples. All specimens were stained with hematoxylin-eosin (H-E) for the histological diagnosis. IHC staining was conducted using serial sections from the same paraffin-embedded blocks as previously described (17, 18). Briefly, all tissue specimens were formalin-fixed and processed similarly, according to standard histological practices. The sections were briefly immersed in citrate buffer [0.01 mol/l citric acid (pH 6.0)] and were incubated for two 10-minute periods at 121°C in a high-pressure sterilization oven for antigen retrieval. They were then incubated with anti-deltaNp63 (PC373, Calbiochem, Darmstadt, Germany) diluted at 1:3000, in phosphate-buffered saline for 60 minutes at 4°C. They were also incubated with anti-HMWCK (34beta E12; keratin-903; Enzo Life Science, Inc, NY, USA) diluted at 1:40, in phosphate-buffered saline for 60 minutes at room temperature. Thereafter, IHC staining of deltaNp63 and HMWCK was performed by the labeled polymer method using Histofine Simple Stain MAX-PO kit (Nichirei, Tokyo, Japan) and EnVision kit (DAKO, Tokyo, Japan) according to the manufacturer's instructions, respectively (18, 19). Negative controls were processed by exclusion of the primary antibody.

Evaluation of the stained specimens. IHC detected the protein expression in each specimen, then the stained cancer cells were evaluated by a combination of proportional and intensity score because the tumor samples showed various degrees of staining intensity and different numbers of positive cells, (20). Initially, 4 degrees of a proportional score (PS) for the positively staining cells were assigned according to the frequency of positive tumor cells (0, none; 1, <25%; 2, 25-50%; and 3, >50%). Thereafter, 4 degrees of an intensity score (IS) were assigned according to the intensity of the staining (none, weak, intermediate, and strong). Normal epithelial cells of the basal of the bronchus showed intense nuclear staining of deltaNp63, which was used as an internal positive control of intensity 2 (20). The slides were independently examined by two of the investigators (H.U. and S.Y.) who were blinded to the clinicopathological data. When a discrepancy was found between the two investigators, a consensus was reached via their simultaneous examination using a double-headed microscope.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of immunostaining in ADSQ tumors.

Results

Figure 1A and C show the H-E staining for the tumor cells. The typical appearance of staining for deltaNp63 is shown in Figure 1B and D. DeltaNp63 expression only clearly stained the nuclei in the SQ component deep brown, whereas HMWCK expression was specifically detected in the cytoplasm. It was easy to discriminate the SQ in ADSQ. DeltaNp63- and HMWCK-expressing tumor cells were observed in 13 (76.5%) and 14 (82.4%) out of 17 cases, respectively. Interestingly, positive expression of deltaNp63 was detected in a case with a negative expression of HMWCK. The opposite was equally true.

Discussion

The discrimination of tumor histology is important for selecting the modality of therapy. Therefore, an accurate histological diagnosis is imperative and a specific marker is needed to detect the SQ component. The incidence of the positive expression of deltaNp63 is significantly higher in SQ than AD (5). Most of the SQ component of ADSQ showed positive expression of deltaNp63 in spite of the genetic intratumoral heterogeneity (21). Therefore, deltaNp63 is a useful marker for its histopathologic diagnosis. Surprisingly, positive expression of deltaNp63 was detected in a case with negative expression of cytokeratin. Nicholson et al. pointed out low the specificity for SQ of 34beta E2 antibody, though HMWCK is useful as a differential marker for SQ (22). DeltaNp63 and HMWCK antibody might compensate each other as an SQ marker. Why is deltaNp63 localized in the SQ component rather than AD? Boldrup et al. reported elevated CD44, which is a marker of cancer stem cells, expression in the clones overexpressing deltaNp63 (12). In fact, deltaNp63 acts as a dominant-negative reagent toward tumor suppressor p53, thus indicating its oncogenic role (23). Higashikawa et al. reported that the epithelial–mesenchymal transition (EMT) is accompanied by a down-regulation of deltaNp63 (25). Cancer cells form a new focus through the mesenchymal–epithelial transition (MET) (26). Therefore, cancer cells in the SQ component might have a more aggressive biological behavior than that of the AD component. In fact, the survival rate for patients with ADSQ is statistically worse than for those with SQ and AD (27). The triangle of relationships among p53 family, EGFR, and EMT might be key in lung cancer translational research (28-30).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A: Representative low-power view of H-E staining of ADSQ (original magnification ×40). B: DeltaNp63-expressing tumor cells with deep brown-stained nuclei are shown for the same specimen and alignment as shown in A. C: Representative high-power view of H-E staining of ADSQ (original magnification ×200). D: DeltaNp63 IHC staining in the same specimen and alignment as shown in C.

No firm conclusion can be drawn from the result of this study because it observed only a small number of patients analyzed at a single institution; nonetheless, the current results apparently indicate that deltaNp63 status is useful as a specific marker of SQ. Further investigation is necessary to determine the clinical benefit of the biomarker in a larger cohort of patients and in prospective studies.

Acknowledgements

We thank Yukiko Koyanagi and Kanako Sasaki and for valuable technical assistance. This work was supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

  • Received September 13, 2010.
  • Revision received October 25, 2010.
  • Accepted October 26, 2010.
  • Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Uramoto H,
    2. Mitsudomi T
    : Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857-863, 2007.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Clément-Duchêne C,
    2. Wakelee H
    : Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review. J Thorac Oncol 5: 129-139, 2010.
    OpenUrlPubMed
  3. ↵
    1. Uramoto H,
    2. Onitsuka T,
    3. Shimokawa H,
    4. Hanagiri T
    : TS/DHFR/GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res, in press.
  4. ↵
    1. Sobin LH,
    2. Wittekind C
    : TNM Classification of Malignant Tumors, 6th ed. New York: Wiley; 2002.
  5. ↵
    1. Uramoto H,
    2. Sugio K,
    3. Oyama T,
    4. Nakata S,
    5. Ono K,
    6. Nozoe T,
    7. Yasumoto K
    : p53 family in lung cancer. Anticancer Res 26: 1785-1790, 2006.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Uramoto H,
    2. Sugio K,
    3. Oyama T,
    4. Nakata S,
    5. Ono K,
    6. Morita M,
    7. Funa K,
    8. Yasumoto K
    : Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Uramoto H,
    2. Wetterskog D,
    3. Hackzell A,
    4. Hackzell A,
    5. Matsumoto Y,
    6. Funa K
    : p73 competes with co-activators and recruits histone deacetylase to NF-Y in the repression of PDGF beta-receptor. J Cell 117: 5323-5331, 2004.
    OpenUrl
  8. ↵
    1. Melino G,
    2. Lu X,
    3. Gasco M,
    4. Crook T,
    5. Knight RA
    : Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28: 663-670, 2003.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hibi K,
    2. Trink B,
    3. Patturajan M,
    4. Westra WH,
    5. Caballero OL,
    6. Hill DE,
    7. Ratovitski EA,
    8. Jen J,
    9. Sidransky D
    : AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97: 5462-5467, 2000.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Massion PP,
    2. Taflan PM,
    3. Jamshedur Rahman SM,
    4. Jamshedur Rahman SM,
    5. Yildiz P,
    6. Shyr Y,
    7. Edgerton ME,
    8. Westfall MD,
    9. Roberts JR,
    10. Pietenpol JA,
    11. Carbone DP,
    12. Gonzalez AL
    : Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63: 7113-7121, 2003.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Parsa R,
    2. Yang A,
    3. McKeon F,
    4. Green H
    : Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099-1105, 1999.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Boldrup L,
    2. Coates PJ,
    3. Gu X,
    4. Nylander K
    : DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 213: 384-391, 2007.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wu M,
    2. Wang B,
    3. Gil J,
    4. Sabo E,
    5. Miller L,
    6. Gan L,
    7. Burstein DE
    : p63 and TTF-1 immunostaining: a useful marker for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 119: 696-702, 2003.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Hu H,
    2. Xia SH,
    3. Li AD,
    4. Xu X,
    5. Cai Y,
    6. Han YL,
    7. Wei F,
    8. Chen BS,
    9. Huang XP,
    10. Han YS,
    11. Zhang JW,
    12. Zhang X,
    13. Wu M,
    14. Wang MR
    : Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer 102: 580-583, 2002.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Glickman JN,
    2. Yang A,
    3. Shahsafaei A,
    4. McKeon F,
    5. Odze RD
    : Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32: 1157-1165, 2001.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Morice WG,
    2. Ferreiro JA
    : Distinction of basaloid squamous cell carcinoma from adenoid cystic and small cell undifferentiated carcinoma by immunohistochemistry. Hum Pathol 29: 609-612, 1998.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Uramoto H,
    2. Osaki T,
    3. Inoue M,
    4. Taga S,
    5. Takenoyama M,
    6. Hanagiri T,
    7. Yoshino I,
    8. Nakanishi R,
    9. Ichiyoshi Y,
    10. Yasumoto K
    : Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462-1465, 1999.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Yamashita T,
    2. Onitsuka T,
    3. Ono K,
    4. Baba T,
    5. So T,
    6. So T,
    7. Takenoyama M,
    8. Hanagiri T,
    9. Oyama T,
    10. Yasumoto K
    : Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer, in press.
  19. ↵
    1. Onitsuka T,
    2. Uramoto H,
    3. Ono K,
    4. Takenoyama M,
    5. Hanagiri T,
    6. Oyama T,
    7. Izumi H,
    8. Kohno K,
    9. Yasumoto K
    : Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
    OpenUrlPubMed
  20. ↵
    1. Iwata T,
    2. Uramoto H,
    3. Sugio K,
    4. Fujino Y,
    5. Oyama T,
    6. Nakata S,
    7. Ono K,
    8. Morita M,
    9. Yasumoto K
    : A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer 50: 67-73, 2005.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Niho S,
    2. Yokose T,
    3. Kodama T,
    4. Nishiwaki Y,
    5. Mukai K
    : Clonal analysis of adenosquamous carcinoma of the lung. Jpn J Cancer Res 90: 1244-1247, 1999.
    OpenUrlCrossRef
  22. ↵
    1. Nicholson AG,
    2. Gonzalez D,
    3. Shah P,
    4. Pynegar MJ,
    5. Deshmukh M,
    6. Rice A,
    7. Popat S
    : Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 5: 436-441, 2010.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Senoo M,
    2. Matsumura Y,
    3. Habu S
    : TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 21: 2455-2465, 2002.
    OpenUrlCrossRefPubMed
    1. Rocco JW,
    2. Ellisen LW
    : p63 and p73: life and death in squamous cell carcinoma. Cell Cycle 5: 936-940, 2006.
    OpenUrlPubMed
  24. ↵
    1. Higashikawa K,
    2. Yoneda S,
    3. Tobiume K,
    4. Taki M,
    5. Shigeishi H,
    6. Kamata N
    : Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 67: 9207-9213, 2007.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Iwatsuki M,
    2. Mimori K,
    3. Yokobori T,
    4. Ishi H,
    5. Beppu T,
    6. Nakamori S,
    7. Baba H,
    8. Mori M
    : Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293-299, 2010.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Shimizu J,
    2. Oda M,
    3. Hayashi Y,
    4. Nonomura A,
    5. Watanabe Y
    : A clinicopathologic study of resected cases of adenosquamous carcinoma of the lung. Chest 109: 989-994, 1996.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Thiery JP
    : Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
    OpenUrlCrossRefPubMed
    1. Herfs M,
    2. Hubert P,
    3. Suarez-Carmona M,
    4. Reschner A,
    5. Saussez S,
    6. Berx G,
    7. Savagner P,
    8. Boniver J,
    9. Delvenne P
    : Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. Am J Pathol 176: 1941-1949, 2010.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Uramoto H,
    2. Iwata T,
    3. Onitsuka T,
    4. Shimokawa H,
    5. Hanagiri T,
    6. Oyama T
    : Epithelial–mesenchymal transition in EGFR-TKI-acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517, 2010.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (11)
Anticancer Research
Vol. 30, Issue 11
November 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
HIDETAKA URAMOTO, SOHSUKE YAMADA, TAKESHI HANAGIRI
Anticancer Research Nov 2010, 30 (11) 4717-4720;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
HIDETAKA URAMOTO, SOHSUKE YAMADA, TAKESHI HANAGIRI
Anticancer Research Nov 2010, 30 (11) 4717-4720;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Tumour suppressor genes in chemotherapeutic drug response
  • Google Scholar

More in this TOC Section

  • Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia
  • Corrigendum
  • Sex-related Survival Differences in Patients With Glioblastoma – Results From a Retrospective Analysis
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire